Our locations are open for appointments and procedures. See how we're providing safe in-person care and telemedicine visits.

(Nuestras facilidades están abiertas para citas y procedimientos. Vea cómo brindamos atención segura en persona y visitas por medio de telemedicina.)
 

Learn More (Aprenda Más)
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Temple University Hospital Begins Recruiting Participants for Phase 3 COVID-19 Vaccine Clinical Trial

View All News

Temple University Hospital will be a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase 3 clinical research study, ENSEMBLE trial, to evaluate the safety and efficacy of the Janssen’s investigational COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S.  

The Phase 3 randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the safety and efficacy of a single vaccine dose of the Janssen COVID-19 vaccine candidate versus placebo, in approximately 60,000 adults 18 years old and older, including significant representation from those that are over 60.

The trial will include those both with and without comorbidities associated with an increased risk for progression to severe COVID-19. 

Temple University Hospital will enroll up to 1,400 adults aged 18 years and older from Philadelphia and the surrounding area. 

ENSEMBLE is being initiated in collaboration with the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Other Transaction Agreement HHSO100201700018C.

More information about the trial is available at www.ensemblestudy.com.